Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
Globe Newswire•01/10/2026•06:45 ET
0
Key Highlights
- ➤HRS-4729 (KAI-4729) 12 mg produced up to 16.0% mean weight loss at Week 12
- ➤HRS-4729 (KAI-4729) 12 mg cut liver fat content 67.3% at Week 12
- ➤Ribupatide 4 mg delivered 16.7% mean weight loss and 38.4% lower liver fat
- ➤Kailera plans KAI-4729 Phase 1 trial outside China in 2026, with data expected in 2027
- ➤Ribupatide injection supported upper-arm and thigh sites with no new safety signals
Expert Statements
Marianne Camargo, MD
“Effect of injection site on the relative bioavailability and safety of ribupatide, a novel dual GLP-1/GIP receptor agonist: Phase 1, randomized, single-dose crossover study result”
- New Phase 1 data highlight flexibility of injection site for ribupatide injection
- Four additional oral presentations from Hengrui Pharma add to the clinical evidence behind Kailera's pipeline
Get started
Create a free account to read the full story.